Experienced in Neonatal Sepsis

Michelle K. Harrison

Chris O'Brien Lifehouse
Camperdown, NSW, AU 
Experienced in Neonatal Sepsis
Chris O'Brien Lifehouse
Camperdown, NSW, AU 
OverviewLocationsClinical Research

Overview

Michelle Harrison practices in Camperdown, Australia. Ms. Harrison is rated as an Experienced expert by MediFind in the treatment of Neonatal Sepsis. Her top areas of expertise are Neurotoxicity Syndromes, Peripheral Neuropathy, Anal Cancer, and Neonatal Sepsis.

Her clinical research consists of co-authoring 59 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Neonatal Sepsis.

Gender
Female

Locations

Chris O'Brien Lifehouse
Camperdown, NSW 2050, Australia
Other Locations
Sydney, NSW, Australia
Hunters Hill, NSW, Australia
Camperdown, VIC, Australia
Brisbane, QLD, Australia
Liverpool, NSW 2170, Australia
QLD, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).
A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).
Enrollment Status: Unknown
Publish Date: February 16, 2022
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
View 1 Less Clinical Trial

59 Total Publications

Is paramedic palliative care different in rural compared to urban settings: A mixed methods study.
Is paramedic palliative care different in rural compared to urban settings: A mixed methods study.
Journal: Palliative medicine
Published: December 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Harrison's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile